Our study revealed that low levels of CD3+ cell (< 565.50 cells/μl), CD4+ cell (< 203.50 cells/μl), and NK cell (< 147.50 cells/μl) were associated with disease progression in COVID-19 patients receiving azvudine treatment. This evidence concerns the gene CD4 and COVID-19.